Sleep and Glycemic Control in Type 2 Diabetes Adolescents
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Children's Hospital of Philadelphia
- Study ID
- NCT04213547
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 20 Years
- Healthy Volunteers
- Not accepted
Interventions
- Loss frame sleep extension intervention — BEHAVIORALAim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
Study Details
The primary objective is to determine the cross-sectional relationship between sleep duration (as measured by 14 days of actigraphy) and glycemic control in an adolescent Type 2 Diabetes (T2DM) cohort (age 12-20y, n=67). A secondary objective is to determine if a loss-framed incentive for achieving sleep goals can increase sleep duration in 15 adolescent patients diagnosed with T2DM with insufficient sleep. Another secondary objective is to test if increasing sleep duration leads to improved glycemic control in 15 adolescents with T2DM identified in Aim 1 as having \<8 hr sleep/evening. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
Key Dates
- Start date
- Sep 16, 2020
- Status verified
- Mar 2026
- Primary completion
- Jun 1, 2026
- Completion
- Jun 1, 2026
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: InterventionThis will be a single-arm study utilizing a loss-framed incentive intervention to induce increased sleep duration.
Primary Outcome Measure
Sleep duration (for Aim 2) [ Time Frame: 13 weeks ]
Central Contacts
- Talia Hitt, MD/MPH215-590-3174
- Beth Schwartzman215-590-3174
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | - |
Find similar trials in Philadelphia, PA
Related Studies
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)PHASE3 · Recruiting · Eli Lilly and Company · Tucson, Arizona
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatidePHASE2 · Recruiting · Eli Lilly and Company · Phoenix, Arizona
- RCT to Assess the Efficacy of Biophoton Therapy to Treat Type 2 DiabetesNot Yet Recruiting · First Institute of All Medicines · Tampa, Florida
- The GRoceries Aimed at Increasing Nutrition StudyRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania